AHA selects five finalists pushing heart and brain care beyond traditional clinic walls
The American Heart Association has narrowed its 2026 Health Tech Competition to five finalists, putting a sharp spotlight on technologies designed to move cardiovascular and brain care out of the limits of conventional workflows. The field spans artificial intelligence, remote physiologic monitoring, digital rehabilitation and tissue engineering, a lineup that reflects how much pressure health systems now face to detect disease earlier, guide therapy sooner and reach patients before deterioration becomes irreversible.
The competition arrives with a familiar clinical problem in the foreground: promising tools often stall before they reach routine care. Adoption depends on more than novelty. A technology has to fit into existing practice, show credible evidence, and solve a real problem for patients and clinicians without adding unmanageable friction. The American Heart Association framed this year’s finalists around that exact gap, selecting companies with clinically informed and validated approaches, early signs of impact and a plausible route to scale.
One sentence captures the stakes: promising digital and biologic tools still fail far too often at the point of implementation.
AI, sensors and tissue engineering occupy the final field
The five finalists represent distinct clinical problems. HEARTio, based in Pittsburgh, is developing investigational AI software that analyzes a standard ECG to estimate obstructive coronary artery disease without dyes, radiation, incisions or catheters. If validated at scale, that approach could matter most in settings where access to advanced imaging is delayed or invasive testing is difficult to arrange. A routine ECG is already embedded in primary care, emergency care and specialty clinics; repurposing it as a screening signal for coronary obstruction would place a new layer of intelligence on a test clinicians already know how to obtain quickly.
MEGI, from Chicago, is building an AI-powered digital health platform focused on women’s heart health, maternal care and hypertension management. That triad is clinically important because pregnancy-related cardiovascular risk often intersects with chronic blood pressure disease, and both can be missed when care is fragmented between obstetrics and cardiology. A platform that keeps those threads together has obvious appeal, especially if it improves surveillance during periods when blood pressure and vascular risk can shift rapidly.
MedRhythms, headquartered in Portland, Maine, is a digital health and neurotherapeutics company combining sensors, software and music to help people improve walking and mobility after neurological injury or disease. In neurologic recovery, gait is not a cosmetic endpoint. It is a proxy for independence, fall risk, daily function and long-term participation in community life. A therapy that targets motor timing and repetition through sensor-guided rhythmic cues fits a plausible rehabilitation mechanism: the nervous system often responds to structured external pacing when internal motor control has been disrupted.
Seerlinq, based in Bratislava, Slovakia, estimates cardiac filling pressure non-invasively from a short fingertip photoplethysmography measurement at home. Its stated clinical aim is early detection of worsening heart failure, catching deterioration weeks before hospitalization so clinicians can adjust therapy in time. Heart failure care is full of this kind of pre-crisis window. Once congestion reaches the hospital, the therapeutic burden rises fast. A home-based signal that tracks hemodynamic change earlier could shift decisions toward outpatient diuresis, medication titration or closer follow-up before the patient crosses into acute decompensation.
Vascudyne, in St. Paul, Minnesota, is developing bioengineered blood vessels that regenerate into the patient’s own tissue. The company’s technology is aimed at coronary bypass patients who otherwise need leg-vein harvest and at children with congenital defects who need an implant that can grow with them. This is the most visibly structural of the five finalists, and for good reason. Vessel replacement remains one of the toughest problems in surgery and pediatric cardiovascular care because the material has to withstand pressure, integrate biologically and endure over time.
Early detection and biologic integration define the commercial bet
The finalists are not competing on novelty alone. Each one tries to solve a common clinical bottleneck: diagnosis that arrives too late, follow-up that breaks down at home, or repair strategies that do not match the body’s own biology. AI tools promise better triage from information clinicians already collect. Sensor-driven platforms try to convert unstable physiologic patterns into actionable signals. Bioengineered vessels aim to replace borrowed tissue with living grafts that may be better suited to long-term use.
For cardiovascular medicine, this mix matters because the field still loses patients to delay. Coronary disease can smolder until the first major event. Heart failure often worsens quietly between visits. Hypertension can remain uncontrolled despite repeated encounters. Pediatric vascular repair brings its own challenge, since current implants do not always grow with the child and may eventually need replacement. The finalists address those failures from different directions, but the common target is the same: earlier, smarter intervention with less procedural burden.
The competition’s selection criteria make that plain. Final presentations will be judged on clinical evidence, scientific innovation and market need. In practice, that means a compelling demonstration must do more than sound futuristic. It has to show supporting data, answer a real unmet need and offer a route into everyday care settings where clinicians are already stretched thin.
Scientific Sessions will stage the public test of these technologies
The finalists will present in the Health Innovation Pavilion during Scientific Sessions 2026 in Chicago, with pitches scheduled for Nov. 7-8 and winners announced Nov. 8. That setting is not incidental. Scientific Sessions is the American Heart Association’s flagship global event for cardiovascular science, which places these technologies in front of clinicians, researchers, investors and industry leaders who influence whether a tool is adopted, studied further or left behind.
The judging panel is intentionally broad, spanning clinicians, researchers, investors and health technology leaders. That mix reflects the actual adoption path for these products. Clinical usefulness matters, but so do workflow integration, reimbursement potential, implementation burden and the ability to survive scrutiny from both science and market forces.
Lee A. Shapiro, the association’s volunteer chair, framed the problem bluntly: too many promising health technologies never reach the people who could benefit from them most. The finalists selected this year are meant to challenge that pattern. Whether they can do so will depend on the strength of their evidence and the degree to which each tool can move from showcase status into routine care without losing clinical rigor.
Selection as a finalist does not constitute endorsement, certification or validation by the American Heart Association, and that distinction remains important. The technologies will now face a more practical test: whether their early data can survive the scrutiny of clinicians who need solutions that work reliably, not just elegantly, across real-world settings. The most consequential question is not which platform sounds most futuristic, but which one can change decisions at the bedside, at home or in the operating room without creating a new layer of complexity.